Curis Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.9%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$27.78next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
| TakeAim CLL Combination Study Initial Data Release | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
TakeAim CLL Zanubrutinib Combination Study Dosing QuarterlyTarget: Dosing of the initial 5 patients
Cash Runway QuarterlyTarget: Fund operations into the second half of 2027
Watch Items
- TakeAim CLL Combination Study Initial DataTrigger: Dosing of the 5th patient to trigger Series B warrant exercise and data releaseAction: Evaluate clinical efficacy and safety data of emavusertib in combination with zanubrutinib
- TakeAim Lymphoma PCNSL Registrational Study EnrollmentTrigger: Full enrollment completion within 12-18 monthsAction: Monitor enrollment velocity and prepare for potential accelerated approval filings in the US and EU
Research as of 20 Jun 2026